Shareholders' Equity

12 Months Ended

Dec. 31, 2022

Stockholders' Equity Note [Abstract]

Shareholders' Equity

Shareholders' Equity

Authorized Shares

We are authorized to issue an aggregate of 60,000,000 shares, all of which are designated as Common Stock having a par value of $0.375 per share. The Board of Directors is authorized to establish one or more series of preferred stock, setting forth the designation of each such series, and fixing the relative rights and preferences of each such series.

Accumulated Other Comprehensive Loss

The changes in components of accumulated other comprehensive loss, net of tax, are as follows:

	Foreign Currency Translation Adjustments		Pension and Postretirement Medical Benefits		Derivative Financial Instruments		Total
December 31, 2020	$	(19.1)	$	(1.7)	$	0.7	$	(20.1)
Other comprehensive (loss) income before reclassifications	(16.9)		(0.4)		10.8		(6.5)
Amounts reclassified from accumulated other comprehensive loss	—		—		(11.3)		(11.3)
Net current period other comprehensive (loss) income	(16.9)		(0.4)		(0.5)		(17.8)
December 31, 2021	$	(36.0)	$	(2.1)	$	0.2	$	(37.9)
Other comprehensive (loss) income before reclassifications	(17.2)		4.8		5.8		(6.6)
Amounts reclassified from accumulated other comprehensive loss	(0.7)		—		(5.0)		(5.7)
Net current period other comprehensive (loss) income	(17.9)		4.8		0.8		(12.3)
December 31, 2022	$	(53.9)	$	2.7	$	1.0	$	(50.2)

Accumulated other comprehensive loss associated with pension and postretirement benefits and cash flow hedges is included in Notes 13 and 11, respectively.

Repurchase of Common Stock

The Board of Directors has authorized the repurchase of 1,112,333 of our common stock. During the year ended December 31, 2022, the Company paid $5.0 million to repurchase 79,756 shares of its common stock at an average price of $62.67 per share. As of December 31, 2022, 1,112,333 shares were available to be repurchased. The Company paid $15.0 million to repurchase 196,982 share repurchases during the year ended December 31, 2021.